Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
Br J Cancer
; 102(1): 115-23, 2010 Jan 05.
Article
en En
| MEDLINE
| ID: mdl-19997099
ABSTRACT
BACKGROUND:
Some cancer patients are immuno-compromised, and it has been long felt that immune-intervention is not compatible with standard chemotherapies. However, increasing evidence suggests that standard chemotherapy drugs may stimulate beneficial changes in both the immune system and tumour.METHODS:
We have assessed the expression of human leucocyte antigen class 1 (HLA1) on tumour cells before and after chemotherapy agents (cyclophosphamide, oxaliplatin or gemcitabine). In addition, we show that chemotherapy-stressed tumour cells may release cytokines that enhance the interactions between dendritic cells (DCs) and T cells into growth media.RESULTS:
Here we report that some chemotherapy agents can increase HLA1 expression in tumour cells, even when expression is low. Increases were associated with killing by cytotoxic T cells, which were negated by HLA1-blockade. Furthermore, T-cell function, as indicated by increased proliferation, was enhanced as supernatants derived from tumours treated with chemotherapy augmented DC-maturation and function.CONCLUSION:
There is evidence that a facet of immune surveillance can be restored by appropriate chemotherapy agents. Also, tumours exposed to some chemotherapy may secrete cytokines that can mature DCs, which ultimately enhances T-cell responses.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma
/
Activación de Linfocitos
/
Linfocitos T Citotóxicos
/
Regulación Neoplásica de la Expresión Génica
/
Antígeno HLA-A1
/
Neoplasias del Colon
/
Presentación de Antígeno
/
Citotoxicidad Inmunológica
/
Antineoplásicos
Límite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Br J Cancer
Año:
2010
Tipo del documento:
Article
País de afiliación:
Reino Unido